What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%
GeneDx leverages AI-driven analytics for healthcare insights; a key insider recently trimmed their stake, according to SEC filings.
Overview
Kevin Feeley, the Chief Financial Officer of GeneDx (NASDAQ:WGS), reported the sale of 3,729 shares of Class A Common Stock for approximately $227,000 on June 16, 2026, following an option exercise and immediate disposition as disclosed in the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($60.77); post-transaction value based on June 16, 2026 market close ($60.77).
Details
* 1-year price change is calculated using June 23, as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.